IHC-specific indicators of FRCT include desmin(+), SMA(+), CD21(‐), CD1a(‐), CD35(‐), and S100(‐).[9,23,24] Studies have shown that lymph node B-type ultrasound, CT, bone marrow morphology, and biopsy examinations are insufficient for diagnosing FRCT, but have important differential diagnostic value.[25] Histopathologically, FRCT should be differentiated from the following tumors:[26,27] (1) FDC tumors; (2) IDC tumors; (3) intranodal palisaded myofibroblastomas; (4) lymphomas; (5) sarcomas; and (6) inflammatory myofibroblastic tumors. This evidence concerns the gene CR2 and inflammatory myofibroblastic tumor.